Parents of premature babies face enough challenges. Trying to access medication that could keep their baby safe from respiratory syncytial virus, a potentially deadly disease, shouldn’t be one of them. But new national data shows that’s the case.
A recently released Institute for Patient Access report card examines insurance claims for palivizumab, the preventive treatment that protects premature infants from RSV. The report card summarizes claims from January through December 2019, including data from both commercial plans and Medicaid.